Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Α. Dimopoulos, Pieter Sonneveld, Javier de la Rubia et al.|Journal of Clinical Oncology|2018Cited by 71
Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on DialysisKarthik Ramasamy, Pieter Sonneveld, Meletios Α. Dimopoulos et al.|Blood|2015Cited by 6
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Igor Wolfgang Blau, Christian Berthou et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety AnalysisKatja Weisel, Pieter Sonneveld, Meletios Α. Dimopoulos et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 2
Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple MyelomaMichèle Cavo, Neil Minton, Luciano Masini et al.|Blood|2011Cited by 1